
    
      This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of
      ALX148 + pembrolizumab and of pembrolizumab alone in patients with metastatic or
      unresectable, recurrent HNSCC that is PD-L1 positive (CPS â‰¥1 by an FDA-approved test) who
      have not yet been treated for their advanced disease. The study comprises an initial safety
      lead-in cohort followed by a randomized portion.
    
  